ASCVD Risk Estimator Plus

Downloads
Revenue

Description

N/A

Screenshots

ASCVD Risk Estimator Plus FAQ

  • Is ASCVD Risk Estimator Plus free?

    Yes, ASCVD Risk Estimator Plus is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is ASCVD Risk Estimator Plus legit?

    🤔 The ASCVD Risk Estimator Plus app's quality is mixed. Some users are satisfied, while others report issues. Consider reading individual reviews for more context.

    Thanks for the vote

  • How much does ASCVD Risk Estimator Plus cost?

    ASCVD Risk Estimator Plus is free.

  • What is ASCVD Risk Estimator Plus revenue?

    To get estimated revenue of ASCVD Risk Estimator Plus app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating
App is not rated in Uzbekistan yet.
Ratings History

ASCVD Risk Estimator Plus Reviews

Doesn't mention bariatric surgery.

mmmmnbdhdjchdhshdbd on

United States

Should include bariatric surgery recommendations for patients that qualify. There are quite a few studies looking at CV risk reduction after surgery. The data should be included in this app. This app appears to ignore a major factor that plays a role (obesity) in about 35% (conservatively) of patients.

Useless

Sunrayyy on

United States

Not calculating, waste time

Not working any longer

Good1981game on

United States

After all of the information is typed in, it is no longer calculating the current 10 yr risk percentage.

Entered age 50, got error

mikephl on

United States

It said the age had to be between 40 and 71

App needs updating

Jazmac on

United States

Please update the app to reflect that aspirin is no longer indicated for primary prevention!

Defective

BigGuy57 on

United States

The app returns an estimated risk based on current data. However the Therapy impact suggests various scenarios that are imprudent. Start HBP meds when the patient doesn’t have HBP. Or intensify Statins for patients whose risk is less than 7.5%

Totally inaccurate

jjmdoc on

United States

This new version has some serious flaws. In addition to being harder to navigate than previous versions, it gives seriously incorrect values for ASCVD risk - last two patients I profiled both came back at 1.1% 10 year risk which is just not possible in the population I am seeing. Last person had a total cholesterol of 334! And still came back as 1.1% risk. Please scrap this version and go back to the old one.

I miss old version

teresa,np on

United States

I miss the old version which included more details on statins with high/moderate vs low intensity statins. A little harder to use now.

Useful app

Internal Med Doc on

United States

The estimation of therapy impact is useful and can be shown to patients so they understand rationale of treatment. The biggest fault is that fields requiring numerical data defaults to letter keyboard. It should automatically bring up the numerical keyboard to ease the burden of data entry.

A new defect

Phred7 on

United States

Thenk you for adding a reset button. But now, when we enter a value (which must be done 5 times) it defaults now to the letter type screen, not the numerical. This requires another keystroke for every number that needs to be entered. This may not sound like much, but since we use it for every patient who gets a lipid panel. this is adding up to a pain. It reminds me too much of my old EHR. Can I somehow revert to the previous version? Thankfully another group has one called the "ASCVD suite" which avoids this wrong screen problem.

Store Rankings

Ranking History
App Ranking History not available yet
Category Rankings
Chart
Category
Rank
Top Free
129
Top Free
137
Top Free
204
Top Free
263
Top Free
268

ASCVD Risk Estimator Plus Installs

Last 30 days

ASCVD Risk Estimator Plus Revenue

Last 30 days

ASCVD Risk Estimator Plus Revenue and Downloads

Gain valuable insights into ASCVD Risk Estimator Plus performance with our analytics.
Sign up now to access downloads, revenue, and more.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.